TY - JOUR
T1 - Treatment of HIV-associated lymphomas
T2 - The latest approaches for optimizing outcomes
AU - Hunter, Natasha B.
AU - Vogt, Samantha
AU - Ambinder, Richard F.
N1 - Publisher Copyright:
© 2019, UBM Medica Healthcare Publications. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Standard regimens, including intensive regimens, are being used with encouraging results in patients with diffuse large B-cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, and primary central nervous system lymphoma. Approaches to salvage therapy also parallel those used in patients without HIV infection, including autologous and allogeneic hematopoietic stem cell transplant. Drug interactions with particular antiretrovirals warrant close attention. At a population level, outcomes in patients with HIV infection and lymphoma remain inferior to outcomes achieved in the general population—but a great deal of progress has been made.
AB - Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Standard regimens, including intensive regimens, are being used with encouraging results in patients with diffuse large B-cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, and primary central nervous system lymphoma. Approaches to salvage therapy also parallel those used in patients without HIV infection, including autologous and allogeneic hematopoietic stem cell transplant. Drug interactions with particular antiretrovirals warrant close attention. At a population level, outcomes in patients with HIV infection and lymphoma remain inferior to outcomes achieved in the general population—but a great deal of progress has been made.
UR - http://www.scopus.com/inward/record.url?scp=85050432054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050432054&partnerID=8YFLogxK
M3 - Article
C2 - 29297171
AN - SCOPUS:85050432054
VL - 31
SP - 872
EP - 884
JO - Oncology
JF - Oncology
SN - 0890-9091
IS - 12
ER -